Drug Development

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

Articles

Enzymatic catalysis offers pharma manufacturers a way to implement the Principles of Green Chemistry.

Going Green with Biocatalysis

Multiple methods are required for detecting and removing protein impurities.

Protein Impurities Pose Challenges

Recent chiral advances demonstrate promise for API synthesis.

Expanding the Chiral Toolbox

Hovione expands drug substance and HPAPI capacity in East Windsor, New Jersey.

Hovione Breaks Ground on API Facility in New Jersey

Effective harvesting and purification processes play an essential role in ensuring that biopharmaceutical manufacturing processes provide biologic drug substances with uniform and consistent properties.

Ensuring Biologic API Uniformity

The collaboration will provide GMP manufacturing ahead of future clinical studies.

CMC Biologics Will Manufacture F-star mAb² Bispecific Antibodies

A new 20,000-L microbial biologics facility in Ireland will be operational by 2018 for Fujifilm Diosynth's contract development and manufacturing customers.

Fujifilm Diosynth Announces Collaboration With MSD on Large-Scale Biologics Facility

Application of flow chemistry for small-molecule API synthesis continues to expand thanks to research efforts.

Steps Closer to the Adoption of Continuous Processing

Xellia, a generic anti-infective drug manufacturing company, is constructing a laboratory services building at its manufacturing site in Budapest, Hungary.

Xellia Builds Testing Services Lab at Budapest Manufacturing Site

Randi Hernandez was science editor at Pharmaceutical Technology from September 2014 to May 2017.

A new study in Nature Communications explores how to remove the bulk of the soaps that are added to injectables to make hydrophobic drugs more soluble.

Ingredients